Researchers from multiple institutions, including the German Cancer Research Center (DKFZ) and the University of Mannheim, published encouraging results from a clinical trial on a vaccine that activates the immune system against a genetic mutation common in gliomas. This type of brain tumor, often incurable, faces significant limitations with chemotherapy and radiation, and is difficult to completely remove surgically.

A glioma is a type of tumor that forms in the brain or spinal cord from glial cells. These cells support neurons. Although it must be clarified that gliomas can be benign or malignant and their severity depends on their location and speed of growth. They can affect both children and adults. They cause symptoms such as vision changes, dizziness, nausea and vomiting, headaches, difficulty communicating, and other cognitive problems.

In the trial, 33 patients newly diagnosed with high-grade gliomas received the vaccine along with standard therapy. After eight years, 66% of participants were still alive, and 42% showed no disease progression. Survival was notably longer among those whose tumors could be removed surgically.

"Our study demonstrates that a vaccination strategy directed against a tumor mutation could generate long-term survival benefits in brain tumors," Michael Platten, director of the Department of Neurology at the University Medical Center Mannheim and head of department at the DKFZ, told Newsweek.

“This opens a new and promising avenue for the treatment of cancers that until now have been difficult to treat,” he stated optimistically.

Immune response and progression

The analysis, published in Nature Cancer, revealed a correlation between the immune response and disease progression. Patients with the best immunological response to treatment showed significantly better prognoses. Additionally, specific T cells were found in participants with controlled tumors, suggesting that immunity could penetrate the tumor.

Research suggests that immunotherapy can be standardized for a broad group of patients by targeting a specific mutation rather than creating personalized vaccines.

A Phase 2 clinical trial is scheduled to begin in 2027, with the intention of testing the effectiveness of this new treatment strategy.

Benign and malignant gliomas

Benign gliomas (generally low grade: grades I–II) and malignant gliomas (high grade: grades III–IV, e.g. glioblastoma) differ in aggressiveness, therapeutic objectives and modalities used: benign ones are usually treated with curative intent through surgery and follow-up, while malignant ones require multimodal treatments (surgery, radiotherapy and chemotherapy) with a focus on local control, delay of progression and palliation.

Diagnosis and treatment objective

Surgery

Radiotherapy and chemotherapy

Monitoring and forecasting

Practical example

You may also be interested in:

· Arsenic, lead and other metals detected in tampons: FDA says they do not pose health risks· You will be surprised! A common supplement in the gym could help fight depression Innovative minimally invasive technique revolutionizes the treatment of knee osteoarthritis